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Abstract: It is well-known that two major issues, preventing improved outcomes from cancer are
late diagnosis and the evolution of drug resistance during chemotherapy, therefore technologies
that address these issues can have a transformative effect on healthcare workflows. In this work
we present a simple, low-cost DNA biosensor that was developed specifically to detect mutations
in a key oncogene (KRAS). The sensor employed was a screen-printed array of carbon electrodes,
used to perform parallel measurements of DNA hybridisation. A DNA amplification reaction was
developed with primers for mutant and wild type KRAS sequences which amplified target sequences
from representative clinical samples to detectable levels in as few as twenty cycles. High levels
of sensitivity were demonstrated alongside a clear exemplar of assay specificity by showing the
mutant KRAS sequence was detectable against a significant background of wild type DNA following
amplification and hybridisation on the sensor surface. The time to result was found to be 3.5 h with
considerable potential for optimisation through assay integration. This quick and versatile biosensor
has the potential to be deployed in a low-cost, point-of-care test where patients can be screened either
for early diagnosis purposes or monitoring of response to therapy.
Keywords: electrochemical; DNA biosensors; KRAS; liquid biopsy
1. Introduction
Cancer is by nature a genetic disease, arising from random mutations and DNA damage which
once reaching a certain threshold result in cellular malfunction. At present, detection of cancer is based
mainly on clinical presentation of symptoms, which often are vague and non-descript. The time point
at which a tumour manifests clinical symptoms often correlates with the later stages of progression
(e.g., Phases III and IV) where surgery and therapy are less effective because of e.g., metastasis or
tumour cells acquiring a critical mass of mutations [1]. At present, once cancer is suspected, referral to
a specialist and the use of imaging techniques such as CT and MRI is the dominant clinical approach to
diagnosis [1]. Once a patient is determined to have a tumour, very often a physical biopsy will be taken
which involves removing a section of the tumour with a needle. A concept that is gaining increasing
traction in cancer diagnosis is the idea of ‘liquid biopsy’ [2]. This is where liquid samples, such as
blood [3], urine [4], cerebrospinal fluid etc., are assayed for biomarkers of cancer. The fact that these
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body fluids are easily accessed by clinicians with minimal damage, risk and pain for the patient means
the approach represents an exciting possibility for assaying biomarkers with the aim of identifying
early stage tumour formation and measuring response to therapy [5,6]. For identifying early stage
tumours via liquid biopsy, a number of potential biomarkers have been proposed, but, two major
classes of markers of particular importance are circulating tumour cells (CTCs) and circulating tumour
DNA (ctDNA) [7]. Both markers have high diagnostic and predictive capability with each having
advantages and disadvantages. Assaying for CTCs means having to concentrate low numbers of
cells (e.g., 10 cells/1 mL blood) for detection whereas assaying for ctDNA means identifying a lower
number of copies of the mutant sequence against a very high background of wild type sequences.
In selecting the approach reported here, ctDNA was chosen as the biomarker because its detection
could potentially be coupled to a DNA amplification reaction and because it allowed the possibility of
developing a multiplexed panel of DNA sequences on a single chip, meaning that commonly mutated
genes could all be identified in parallel (e.g.,KRAS, TP53, BRCA1&2, IDH-1, etc.,). This approach of
developing biomarker ‘panels’ is thought to be one of the key advantages of the approach [8].
Electrochemical DNA biosensors represent an exciting approach to the fast, low-cost detection
of clinically important biomarkers [9,10] at the point of care [11]. A range of electrode materials
and electrochemical measurement approaches have been employed for sensitive measurements
(cyclic voltammetry [12], differential pulse voltammetry [13], square wave voltammetry [14]
and electrochemical impedance spectroscopy [15]). The potential of electrochemical biosensors,
once matured as a technology to provide efficient clinical workflows is immense. The topic of liquid
biopsies is one such area where innovations in biomarker detection will enhance clinical outcomes
for patients [16]. Electrochemical systems for ctDNA detection or cancer biomarker detection have
most often employed the ‘three electrode system’ where the working electrode is functionalised with a
nucleic acid probe sequence and then interrogated using some measurement techniques to determine
recognition of the target molecule [17]. In addition to the evaluation of potential measurement and
signal amplification schemes, the importance of the underlying electrode has also been investigated
through the use of e.g., nanostructured gold electrodes [18]. What these advances have so far reported
are complex assays involving the use of modified oligonucleotides [19], formation of branched structures
upon DNA recognition [20], molecular switches [21], nanostructured electrode modifications [18],
etc., therefore ultimately having a limited chance of manufacture and clinical uptake. The current
state-of-the-art in terms of general nucleic acid liquid biopsies [22] and electrochemical detection of
ctDNA biomarkers [23] have been well-reviewed recently.
This work presents a KRAS G12D DNA oligonucleotide probe-modified sensor which when
coupled to a PCR reaction detects mutated amplicons from a significant background of human DNA and
in particular KRAS wild type sequences (KRAS G12D mutation occurs at position 35 on chromosome
12 changing glycine to aspartic acid in the protein structure). The advantage of our approach is its
simplicity. A straightforward covalent attachment is used to couple a simple amine-modified DNA
sequence (e.g., no tethered labels or redox intercalators) to a simple screen-printed carbon electrode
which is then interrogated using cyclic voltammetry (CV) to reveal DNA hybridisation and thus
mutation detection in potassium ferri-ferrocyanide solution. Because of the simplicity of the approach
presented herein and the choice of steps employed in the assay, the system can be very easily automated
and integrated into a final device capable of fast and seamless clinical measurements. Since the assay
has been deliberately engineered to be simple, low-cost and employs well-established methodologies
such as PCR, the hope is that it will lead to faster clinical adoption.
2. Materials and Methods
2.1. Reagents
Droplet digital PCR (ddPCR) assays, Supermix for probes, DG8TM cartridges and Droplet
Generation Oil were obtained from BioRad Laboratories Ltd., UK. Deionised water, sodium chloride,
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phosphate buffered saline (PBS), sodium nitrate, 4-aminobenzoic acid, hydrochloric acid, ethanolamine,
2-(N-morpholino) ethanesulfonic acid (MES), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
hydrochloride (EDC), N-hydroxysuccinimide (NHS), potassium ferricyanide, potassium chloride and
potassium ferrocyanide were all purchased from Sigma-Aldrich (Dorset, UK). 250 units HotStarTaq Plus
and dNTP Mix, PCR Grade (200 µL) were purchased from Qiagen, (Manchester, UK). Phusion direct
PCR kit was purchased from thermo scientific, (Renfrew, UK).
2.2. Electrochemical Setup
Screen printed multi carbon electrodes (DRP 8W110) as shown in Figure 1 below, were obtained
from DropSens (Oviedo, Spain) with chip dimensions of 50 × 27 × 1 mm (L × W × D). The chip
contained eight carbon working electrodes with diameters of 2.95 mm with a carbon counter and silver
reference electrode. The screen printed fabrication process is specified by the manufacturers.
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2.3. Electrochemical Measurements and Surface Functi lis tion
DNA hybridisation experiments were performed using a covalently attached layer of
single-stranded DNA probes. The surface functionalisation protocol is illustrated in Figure 1. To prepare
the surface of the carbon electrodes for DNA probe attachment it was necessary to first use a surface
pretreatment by applying 1.4 V for 1 min in 0.5 M acetate buffer solution (ABS) containing 20 mM NaCl
8 (pH 4.8). Next, 2 mM NaNO2 solution with 2 mM 4-aminobenzoic acid was prepared in 0.5 M HCl
and stirred for about 5 min at room temperature to produce a diazonium compound. The activated
diazonium solution was then scanned using cyclic voltammetry from +0.4 to −0.6 V at a scan rate of
100 mV/s followed by a wash with DI water. The resulting 4-carboxyphenyl (AP) film was activated
on the electrode surface with 100 mM EDC and 20 mM NHS in 100 mM MES buffer (pH 5.0) for
60 min to form an ester that allowed for efficient conjugation to the amine modified ssDNA probe
(Figure 1). Unless specifically stated, all the reported steps and measurements were carried out at
room temperature.
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2.4. Genomic DNA Sample Preparation, DNA Probe Design and Sample Amplification
For assay development, copies of the KRAS pG12D mutant and wild type DNA were amplified
from genomic DNA (gDNA) isolated from SK-UT-1 cells. Levels of both mutant and wild type
DNA were determined using ddPCR assays (KRA p.G12D c.35G>A, assay ID dHsaCP000001and
KRAS WT for p.G12D c.35G>A, assay ID dHsaCP2000002) in combination with a QX200TM Droplet
DigitalTM PCR system (Biorad Laboratories Ltd., Hertfordshire, UK) following the manufacturer’s
instructions. Briefly, 5–10 ng of gDNA isolated from SK-UT-1 cells- was mixed with ddPCR Supermix
for probes (N0 dUTP) and florescein amidite (FAM)-labelled KRAS p.G12D primers/probe and
hexachloro-fluorescein 9 (HEX)-labelled KRAS WT primers/probes, in the presence of restriction
enzyme and in a volume of 20 µL. Reaction samples were loaded onto a DG8TM cartridge with 70 µL
of Droplet Generation Oil for Probes according to the Droplet Generator Instruction Manual (Biorad
Laboratories Ltd., UK). PCR cycling conditions for the generated droplets were as follows: initial
enzyme activation at 95 ◦C for 10 min, followed by 40 cycles of denaturation at 94 ◦C for 30 s and
annealing/extension at 55 ◦C for 1 min, after which ended with a final enzyme deactivation at 98 ◦C for
10 min. Data acquisition after thermal cycling, was performed using the QX200 Droplet Reader and
the QuantaSoft Software (Biorad Laboratories Ltd., Hertfordshire, UK).
The design of PCR primers and probes used in this study was based on the published sequence
of KRAS pG12D under accession number NC_000012.12 (NCBI, 2019). Amine-modified synthetic
oligonucleotides (KRAS G12D) designed as shown in Table 1 below with a concentration of 200 µM
were obtained from Sigma-Aldrich, UK and stored at −80 ◦C prior to aliquoting for use as probes.
A wild type probe (without the single base mutation) was also designed for use as a negative control.
DNA probe stocks were diluted to a concentration of 20 µM in 0.1 × PBS prior to immobilisation.
Primer-BLAST software was used to design the PCR primers employed in this study. The forward
primers had a GC content of 55% while the reverse primer had a GC content of 39.13% with an
estimated product length of 88 with low self-complementarity.
Table 1. List of DNA sequences employed in this study.
KRAS Probe and Primer Sequences
23 bases Wild type Probe AGTTGGAGCTGGTGGCGTAGGCA
23 bases Mutant Probe AGTTGGAGCTGATGGCGTAGGCA
Forward Primer (Wild type) TGTGGTAGTTGGAGCTGGTG
Forward Primer (Mutant) TGTGGTAGTTGGAGCTGATG
Reverse Primer TTGTGGACGAATATGATCCAACA
For standard PCR amplification, samples of extracted wild type and KRAS G12D mutated DNA
were amplified using the HotStar Taq plus DNA polymerase with 10 ×P CR Buffer, dNTP mix,
Q-solution and primer solutions (Qiagen, UK). Template DNA (≤1 µg/100 µL reaction) was added to
individual PCR tubes containing the pre-prepared reaction mix and the thermal cycler was programmed
to start with an initial heat-activation step at 95 ◦C for 5 min. Temperatures specifications for denaturing,
annealing and extending were set at 1 min for 94 ◦C, 65 ◦C and 72 ◦C respectively. A final extension for
10 min at 72 ◦C was set and PCR conditions were systematically varied by employing cycle numbers
of 20, 25 and 30. PCR amplification of wild type and KRAS G12D samples was performed using the
minipcr thermal cycler and amplicons were characterised using the minipcr blueGel Analyser with
1.5% agarose gel electrophoresis at 140 V for 40 min (Amplyus, 2017).
The phusion blood direct PCR Kit protocol and reaction setup guide outlined by Thermo Scientific,
UK was used to amplify the mutants in the total isolated DNA spiked into human plasma. Phusion
blood II DNA polymerase (1 µL), 2 × PCR Buffer (25 µL), 50 mM EDTA (2.5 µL), 50 mM MgCl2 solution
(1.5 µL) and 100% DMSO (2.5µL) were all included in the reaction mix and dispensed into appropriate
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PCR tubes. Total of 1 µL template DNA, 5 µL forward and reverse primers and 10 µL ultrapure
water were added to the master PCR tube containing the reaction mix and the thermal cycler was
programmed to start with an initial heat-activation step at 98 ◦C for 300 s. Temperatures specifications
for denaturing, annealing and extending were set at 90 s for 94 ◦C, 65 ◦C and 72 ◦C respectively. A final
extension for 60 s at 72 ◦C was set and PCR conditions was set for 37 cycles. PCR was performed using
the minipcr thermal cycler and PCR amplification products were confirmed using minipcr blueGel at
1.5% agarose gel electrophoresis at 140 V for 40 min [24].
3. Results and Discussion
3.1. Assay Workflow and DNA Amplification
Prior to carrying out any work on the electrochemical detection of the KRAS G12D mutation, it was
necessary to first confirm the presence of mutated DNA in the representative sample. These samples
were clinically derived from cancer patients and were employed for assay development to give
confidence that the sensor indeed could work with clinical samples. This was done using droplet
digital PCR on DNA samples isolated from patients. From Figure 2, it can be seen that the levels of
mutated KRAS G12D gDNA were low (~4 copies/ng of total DNA) compared to the wild type KRAS
(~550 copies/ng of total DNA). This finding was reassuring, i.e., that KRAS G12D mutations were
present in the assay samples but underlined the analytical challenge of amplifying the mutation against
a high background of wild type KRAS DNA sequences and also the high genomic DNA background
more generally.
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In order to couple DNA amplificatio i lectrochemical assay, it was n cessary to
dev lop a standard PCR reaction which e c rtable PCR machine manufactured
by ‘min pcr’ (Cambri , , USA) to closely imic a system which could be deploy d i the
clinic. To produce a working PCR reaction, primer sets were designed which would specifically
amplify the KRAS G12D-mutated sequence or the wild type KRAS sequence. The final sequences are
shown in Table 1 (see Materials and Methods section) with the reaction being designed to utilise a
common reverse primer. The ability of the primer sets to successfully amplify both the KRAS G12D
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mutant sequence and the KRAS wild type sequence was confirmed by gel electrophoresis and through
measurement on a Qubit fluorometer. These results confirmed our ability to amplify and quantify
mutated and wild type sequences from the KRAS G12D sample for electrochemical detection.
Having established both the presence of low copy numbers of KRAS G12D mutations in the
sample and an amplification reaction which could produce either mutated or wild type amplicon
depending on primer choice, the next stage involved successfully establishing an electrochemical
measurement to verify the presence of either wild type or mutant DNA.
3.2. Initial Assay Development
Carbon has many advantages that led to its selection as the electrode material in this work.
These include: low-cost production, the existence of many established manufacturing process for carbon
SPE production, high resistance to biofouling and well established surface functionalisation chemistries.
The existence of a multi carbon electrode chip (8 × working electrodes) already commercially available
from DropSens (Oviedo, Spain) meant that there was an established format available for initial
assay development. With a carbon electrode in hand, it was necessary to implement a surface
functionalisation chemistry and to this end functionalisation with a diazonium compound followed
by NHS-EDC coupling of amine-tagged DNA, the electrode surface was implemented. This is a
well-established and robust methodology for biofunctionalising carbon surfaces for electrochemical
readout of bio-recognition events [25,26]. The chip itself and a flow diagram of the functionalisation
protocol are shown in Figure 2, full details of the electrode biofunctionalisation process are given
in the materials and methods section. Specific probe sequences for the G12D mutant and wild type
KRAS sequences were designed, specifically for optimal discrimination of single base-pair changes.
Previous work on electrochemical detection of single base-pair changes has demonstrated enhanced
discrimination and optimal signal levels when the mutation is placed close to the centre of the probe
sequence [26].
In order to evaluate the specificity of the assay, we explored the ability of the probe-modified
electrodes to discriminate between G12D mutant and wild type KRAS sequences. To investigate
specificity levels and gain an initial impression of assay sensitivity, a series of electrodes were
functionalised with KRAS G12D mutant and wild type probe. The results of these experiments are
summarised in Figure 3, which shows the percentage change in the reductive peak current following
target hybridisation. For macroscale electrodes functionalised with biological molecules such as
DNA or antibodies the expectation is that cyclic voltametric peak currents will reduce upon target
hybridisation. For impedimetric measurements, it is expected that the charge transfer-resistance (RCT)
will increase. This is because the presence of greater amounts of DNA at the electrode surface (brought
about by target hybridisation) will lead to both electrostatic repulsion of the redox mediator and steric
hindrance around the interface, causing a reduction in mass transport limited currents, manifesting
in reduced peak heights in voltammetry and increased charge transfer-resistance in EIS. It has been
observed that these effects can be reversed when micro or nanoscale electrodes are employed [10,27],
but for this study, the electrodes were comfortably employed on the macro scale (diameter = 2.95 mm).
Therefore, we would expect a reduction in peak current when specific DNA hybridisation took place
and this was found to be the case. When the wild type sequence was hybridised with the mutant
PCR product, reductions in the peak current were not observed indicating no significant hybridisation.
These findings were highly satisfying, i.e., surface tethered KRAS G12D mutant probe sequence could in
fact discriminate between the mutant and wild type sequences from the PCR product). This represented
a double specificity for the PCR-based assay because the primer design had already been shown to
specifically amplify the mutated sequence so coupling the specificity of the electrochemical probe
sequence meant that the assay would be able to specifically identify mutant amplicons from the sample.
Having established the specificity of the assay and the nature of the electrochemical change, the next
step involved verifying the sensitivity of the assay and dose response effects for the KRAS G12D
mutant PCR product.
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Figure 3. CV results showing hybridisation selectivity between a (a) wild type probe (b) mutant
probe and a representative sample containing PCR amplified KRAS G12D mutant allele with a total
KRASG12D ssDNA concentration of 0.854 ng/µL.
With a functionalised electrode surface, it became necessary to evaluate the reproducibility and
stability of the multi-carbon electrode chip. The repeatability of the proposed sensor was evaluated by
performing 8 replicates using the same SPCE sensor and ferricyanide solution (Figure 4). The data
(n = 8) show less variation and more consistency in the signal change. This shows good reproducibility
of the SPCE sensor when functionalised with DNA and means that the measurements are easier to
interpret. All ferri-ferrocyanide solutions were cycled on the 8-chip multielectrodes (un and DNA
functionalised) × 3 times using CV scans from +0.4 to −0.6 V at a scan rate of 100 mV/s with current
ranges between 10 nA and 10 mA.
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3.3. Assay Optimisation
With the basis of the assay established, i.e., PCR primer specificity, ssDNA probe specificity and
electrochemical signal changes of the correct direction and magnitude, it was important to investigate
whether dose-response effects could be established and whether an optimal number of PCR cycles
could be identified to reduce sample to result time. First of all, it was decided to investigate the effect
of the number of PCR cycles employed for amplification on the electrochemical signal change post
hybridisation. For this work, both cyclic voltammetry (CV) and electrochemical impedance (EIS)
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measurements were performed in order to determine whether consistent behaviour was observed
using the two techniques. Figure 5 shows two example of impedance results showing the changing
signal levels for electrodes incubated with PCR product generated from 25 and 30 cycle reactions. It can
be seen that the increase in the charge transfer resistance (RCT) semi-circle and equivalent circuit fitting
using the well-established Randles’ equivalent circuit were expected. For clarity, the expected trend
was observed in that RCT increased from clean electrode, to ssDNA mutant probe-modified surface, to
target hybridisation with all steps providing clear indication of increased blocking of the electrode
surface. Furthermore, the increase in RCT from the probe modification to the target hybridisation
step was greater for the 30-cycle PCR reaction when compared to the 25-cycle reaction hinting at a
dose response effect, since the 30 cycle reaction would have produced significantly more PCR product
(see Figure S1 for RCT values). This was an encouraging finding but repeated functionalisation with
ssDNA probe and target hybridisation across multiple sensor chips led to a wide range of impedance
responses, sometimes with the response having a profile that was difficult to fit to any established
equivalent circuit. Because of this high variation in the impedance response it was decided to focus
on voltammetry measurements because these showed high consistency across sensor chips with
variation in signal profile significantly reduced. Figure 5c shows an example response and how both
the reductive and oxidative currents reduced in a systematic fashion as PCR cycle number increased.
This finding was encouraging because it demonstrated clear discrimination between the baseline
response and the response following incubation with a 20 PCR cycle KRAS G12D amplicon meaning
detection was possible in as few as 20 PCR cycles.
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3.4. DNA Target Controls
After analysing the specificity of the developed DNA sensor, it was necessary to investigate the
response effects using assay negative controls. In Figure 6 below, samples investigated ‘as Target
hybridisation negative controls’ were ultrapure water and human plasma. In these plots, low signal
change arise from small reduction in oxidative peak current post hybridisation. The ultrapure water
and plasma showed low signal changes upon hybridisation using a mutant probe. This result is
comparable with the hybridisation selectivity performed in Figure 3 with KRAS DNA amplicons.
The wide error bars from the plasma immobilisation are assumed to be due to inter-electrode variability
and different fragment lengths of non-specific DNA in plasma (especially wild type KRAS) binding
to the mutant probe. The hybridisation between the G12D mutant probe and plasma highlights the
importance of mutant amplification and is very important as the concentration of circulating free DNA
released by tumour cells is usually in proportion to the stage of cancer [28]. After exploring DNA
hybridisation controls, it was necessary to investigate the concentration response effects to confirm the
potential for quantitation. In Figure 6b, the concentration response for a 25-cycle PCR product diluted
to different concentrations was explored in order to gain an impression of potential detection limits.
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The sample with the lowest concentration (0.027 ng/µL) showed the lowest percentage signal change
upon hybridisation. As circulating nucleic acids are present in blood at ng/mL levels, which based on
the fragment length is analogous to a picomolar concentration, a minimum of femtomolar sensitivity
will be beneficial for detection of tumour-specific sequences without amplification [16]. Whilst a
reduction in signal was observed after incubating both the mutant probes in samples of plasma spiked
with DNA from the representative patient samples, it is important to note that signal reductions were
not as large i.e., a whole mutant amplification reaction when incubated on the sensor brought about
much larger decreases in signal, e.g., >80%. This is important because at present, whilst dose response
is achievable, the assay was run as a ‘threshold’ test with interrogation of a whole amplification reaction
giving rise to clear, detectable changes (above negatives) when the KRAS G12D mutation was present.
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The workflow implemented in this assay had a total time to result of 3.5 h. As things currently
stand this is very competitive with established clinical approaches to characterising tumour samples
e.g., standard pathology techniques. In theory, a tumour can be typed by established techniques
in 2–3 days, in practice, using the example of the UK NHS it can take up to 9 weeks in total for
results to be confirmed. Therefore, this approach is well positioned to offer substantial cost and
time savings to healthcare systems. In addition, the workflow reported is entirely un-optimised
with considerable potential for producing a result more quickly through use of isothermal DNA
amplification techniques, integration with sample handling technologies and full optimisation of the
electrodes and electrochemical measurements procedure, e.g., use of pulsed voltametric techniques in
order to heighten sensitivity.
By combining a PCR reaction designed to amplify KRAS mutations from clinical samples
it has been possible to demonstrate the detection of G12D mutations by electrochemical means.
The electrochemical detection system employed was deliberately designed to be simple and utilise
low cost materials in order to result in a cost-effective test once commercialised. The generic nature of
the techniques involved, i.e., surface attachment chemistry, PCR, ssDNA probes and electrochemical
detection mean that the assay can be very easily enlarged by changing primer and probe sequences
to match the mutations required. For example, many common liquid biopsy markers: KRAS, TP53,
BRCA1&2 can be detected via this method to give a panel of markers on the electrode array. This will
lead to the ability to screen for common cancerous mutations in fast times and at low cost in the clinical
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environment. In addition to this, the approach can be used to monitor treatment response and give
early warning of relapse.
4. Conclusions
It was possible to design a PCR reaction capable of amplifying either mutant KRAS G12D or wild
type KRAS through primer choice from patient samples. In parallel, an electrochemical detection
scheme involving cyclic voltammetry and carbon screen printed electrodes was developed and shown
through a series of comparative measurements to be sensitive and specific for the KRAS G12D mutation.
Electrochemical impedance spectroscopy measurements were halted because of the inconsistency of the
response and difficulties with equivalent circuit fitting. Cyclic voltammetry measurements provided
the desired response and showed detection was possible from samples containing 4 copies/ng total
DNA in as few as 20 PCR cycles. In addition, the response was found to be consistent, i.e., large signal
decreases being evident upon amplification of the mutant allele, offering promise of quantitation of
mutant sequences from clinical samples. Sources of potential signal contamination were examined and
found to not contribute significantly to the analytical response, giving confidence that signal changes
were not due to other binding effects from the sample solutions. These results raise the prospect
of simple, rapid, cost effective measurement of nucleic acid tumour markers from blood and other
body fluids.
Supplementary Materials: The following are available online at http://www.mdpi.com/2079-6374/10/11/156/s1,
Figure S1: Equivalent circuit models of the impedance spectra recorded for SPCE (a) 25 PCR thermal cycles
pre-hybridisation (b) 25 PCR thermal cycles post-hybridisation (c) 30 PCR thermal cycles pre-hybridisation (d) 30
PCR thermal cycles post-hybridisation.
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